Megakaryocyte and platelet ontogeny

巨核细胞和血小板个体发育

基本信息

  • 批准号:
    8694029
  • 负责人:
  • 金额:
    $ 33.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-07-01 至 2018-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Platelets are anucleate cells derived from megakaryocytes (megs) that serve as critical components of hemostasis and thrombus formation, and mediate aspects of inflammation, immunity, and angiogenesis. In the adult, all platelets are derived from hematopoietic stem cells (HSCs). We previously discovered in the mouse embryo that the meg lineage is specified several days before HSC emergence as embryonic (pre- HSC) megakaryopoiesis. We have also determined that embryonic megs have limited polyploidization and generate extremely large platelets with small a-granules. Thrombopoiesis in human neonates is also characterized by limited polyploidization and rapid cytoplasmic maturation. Endoreplication is regulated in part by the Cip/Kip family of cell cycle inhibitors. Our preliminary studies indicate that embryonic, but not adult, platelets express high levels of p57 (Kip2). In Aim 1, we will further define the differences between embryonic, fetal and adult megakaryopoiesis and test the hypothesis that differences in meg endoreplication are regulated, in part, by the differential expression of Cip/Kip family members. Our preliminary studies of primary embryonic platelets indicate that they are effectively activated by thrombin but markedly less so by ADP. These functional studies correlate with the differential upregulation of PAR1 and down-regulation of P2Y12 in primary embryonic versus adult platelets. In Aim 2 studies, we will test the hypothesis that embryonic platelets have intrinsic functional differences in activation and clot formation when compared to their adult counterparts. An understanding of hematopoietic ontogeny is particularly relevant to the generation of blood cells from embryonic stem (ES) cells and induced pluripotent stem (iPS) cells, which carry the potential to serve as an important source of cell-based therapies. We hypothesize that ES cell-derived megs and platelets will have predominantly embryonic characteristics. This hypothesis will be tested by comparing ES cell-derived meg maturation and platelet function with that of primary embryonic cells. This proposed research builds upon our studies of meg ontogeny and platelet emergence in the murine embryo and establishes a foundation for the development of clinically useful cell-based therapies from ES/iPS cell sources.
描述(由申请人提供):血小板是源自巨核细胞(megs)的无核细胞,是止血和血栓形成的关键成分,并介导炎症、免疫和血管生成。在成人中,所有血小板都来自造血干细胞(HSC)。我们先前在小鼠胚胎中发现,在HSC出现前几天,meg谱系被指定为胚胎(前HSC)巨核细胞生成。我们还确定胚胎megs有有限的多倍化,并产生非常大的血小板与小的α-颗粒。人类新生儿中的血小板生成也以有限的多倍化和快速的细胞质成熟为特征。胞内复制部分受细胞周期抑制剂Cip/Kip家族调节。我们的初步研究表明,胚胎,但不是成人,血小板表达高水平的p57(Kip 2)。在目标1中,我们将进一步定义胚胎,胎儿和成人巨核细胞生成之间的差异,并测试的假设,在梅格endoreficit的差异调节,部分,由Cip/Kip家族成员的差异表达。我们对原代胚胎血小板的初步研究表明,它们能被凝血酶有效激活, ADP的情况明显较低。这些功能研究与原代胚胎血小板与成人血小板中PAR 1的差异上调和P2 Y12的下调相关。在目标2研究中,我们将检验胚胎血小板具有内在功能差异的假设 与成年人相比,它们的激活和血栓形成。对造血个体发生的理解与从胚胎干(ES)细胞和诱导多能干(iPS)细胞产生血细胞特别相关,其具有作为基于细胞的疗法的重要来源的潜力。我们假设ES细胞来源的MEG和血小板将主要具有胚胎特征。将通过比较ES细胞来源的meg成熟和血小板功能与原代胚胎细胞的功能来检验这一假设。这项拟议的研究建立在我们对小鼠胚胎中巨细胞个体发育和血小板出现的研究基础上,并为从ES/iPS细胞来源开发临床有用的基于细胞的疗法奠定了基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James Palis其他文献

James Palis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James Palis', 18)}}的其他基金

Embryonic natural killer cell development and function
胚胎自然杀伤细胞的发育和功能
  • 批准号:
    10661496
  • 财政年份:
    2021
  • 资助金额:
    $ 33.39万
  • 项目类别:
Embryonic natural killer cell development and function
胚胎自然杀伤细胞的发育和功能
  • 批准号:
    10328573
  • 财政年份:
    2021
  • 资助金额:
    $ 33.39万
  • 项目类别:
Megakaryocyte and platelet ontogeny
巨核细胞和血小板个体发育
  • 批准号:
    8829970
  • 财政年份:
    2013
  • 资助金额:
    $ 33.39万
  • 项目类别:
2013 Red Cells Gordon Research Conference & Gordon Research Seminar
2013 红细胞戈登研究会议
  • 批准号:
    8525933
  • 财政年份:
    2013
  • 资助金额:
    $ 33.39万
  • 项目类别:
Megakaryocyte and platelet ontogeny
巨核细胞和血小板个体发育
  • 批准号:
    9043868
  • 财政年份:
    2013
  • 资助金额:
    $ 33.39万
  • 项目类别:
Megakaryocyte and platelet ontogeny
巨核细胞和血小板个体发育
  • 批准号:
    8478982
  • 财政年份:
    2013
  • 资助金额:
    $ 33.39万
  • 项目类别:
Megakaryocyte and platelet ontogeny
巨核细胞和血小板个体发育
  • 批准号:
    9264520
  • 财政年份:
    2013
  • 资助金额:
    $ 33.39万
  • 项目类别:
Role of EPO in terminal erythroid maturation
EPO 在终末红细胞成熟中的作用
  • 批准号:
    8685321
  • 财政年份:
    2012
  • 资助金额:
    $ 33.39万
  • 项目类别:
Role of EPO in terminal erythroid maturation
EPO 在终末红细胞成熟中的作用
  • 批准号:
    8875051
  • 财政年份:
    2012
  • 资助金额:
    $ 33.39万
  • 项目类别:
Role of EPO in terminal erythroid maturation
EPO 在终末红细胞成熟中的作用
  • 批准号:
    8417125
  • 财政年份:
    2012
  • 资助金额:
    $ 33.39万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.39万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 33.39万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 33.39万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 33.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 33.39万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 33.39万
  • 项目类别:
    Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
  • 批准号:
    2230829
  • 财政年份:
    2023
  • 资助金额:
    $ 33.39万
  • 项目类别:
    Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 33.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 33.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 33.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了